Inspire Medical Systems Inc

Inspire Medical Systems Inc(INSP)股票分析

$61.440

+0.627 (+1.02%)收盘时

Loading chart…
High
62.050
Open
60.520
VWAP
61.33
Vol
517.99K
Mkt Cap
4.02B
Low
60.500
Amount
31.77M
EV/EBITDA, TTM
112.60

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

AI analysis of Inspire Medical Systems Inc (INSP)

buy

Inspire Medical Systems Inc is a good buy right now due to its strong Q2 earnings performance, reporting a non-GAAP EPS of $0.14, which exceeded expectations by $0.39. Additionally, the company raised its 2026 revenue outlook to between $835 million and $875 million, indicating confidence in future growth. The current price of $61.44 is significantly below the analyst price target of $85, suggesting a potential upside of 38.3%. However, the forward P/E ratio is extremely high at 1111.11, indicating that the stock may be overvalued if growth does not materialize as expected.

Analyst Ratings (5)

+136.51% upside
Buy
3 Buy
2 Hold
0 Sell
Current: 61.44
最低
91.00
平均
145.31
最高
180.00

Mizuho

2026-08-04

目标价

$65

Outperform

JPMorgan

2026-08-04

目标价

$60

Neutral

Evercore ISI

2026-08-04

目标价

$54

In Line

BofA

2026-08-04

目标价

$45

Underperform

Truist

2026-08-04

目标价

$62

Hold

估值指标

The current forward P/E ratio for Inspire Medical Systems Inc (INSP) is 1111.11, compared to its 5-year average forward P/E of 41.23.

Forward P/E

Strongly Overvalued
5Y Average P/E
41.23
Current P/E
1111.11
高估
289.36
低估
-206.90

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-3.90
Current EV/EBITDA
112.60
高估
166.50
低估
-174.30

Forward P/S

Undervalued
5Y Average P/S
8.92
Current P/S
2.00
高估
14.99
低估
2.85

Alphio AI Price Scenarios for INSP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%INSP

$195.33

情景价格

B

Base

Base · 50%INSP

$174.83

情景价格

B

Bear

Bear · 25%INSP

$166.61

情景价格

Whales holding INSP

S

Soleus Capital Management, L.P.

+ HoldingINSP

+3.63%

3M Return

A

ADAR1 Capital Management, LLC

+ HoldingINSP

+2.25%

3M Return

事件时间线

2026-08-04 (ET)

12:00:00

Major Averages Surge Again, Tech Shares Lead Gains

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

16:30:00

Company Narrows FY26 Revenue Outlook to $835M-$875M

16:30:00

Inspire Medical Reports Q2 Revenue of $200.6M, Beating Consensus

16:30:00

Company Announces Strategic Growth Plan with Restructuring Costs of $25 Million

资讯

INSP FAQ — answered by Alphio AI

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Inspire Medical Systems Inc is a good buy right now due to its strong Q2 earnings performance, reporting a non-GAAP EPS of $0.14, which exceeded expectations by $0.39. Additionally, the company raised its 2026 revenue outlook to between $835 million and $875 million, indicating confidence in future growth. The current price of $61.44 is significantly below the analyst price target of $85, suggesting a potential upside of 38.3%. However, the forward P/E ratio is extremely high at 1111.11, indicating that the stock may be overvalued if growth does not materialize as expected.

5 analysts cover INSP: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 145.31.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始